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Abstract
The randomized “Testicular cancer and Aerobic and Strength Training trial” (TAST-
trial) aimed to evaluate the effect of high-intensity interval training (HIIT) on cardiore-
spiratory fitness during cisplatin-based chemotherapy (CBCT) for testicular cancer
(TC). Here, we report on an unexpected high number of thromboembolic (TE) events
among patients randomized to the intervention arm, and on a review of the literature
on TE events in TC patients undergoing CBCT. Patients aged 18 to 60 years with a
diagnosis of metastatic germ cell TC, planned for 3 to 4 CBCT cycles, were random-
ized to a 9 to 12 weeks exercise intervention, or to a single lifestyle counseling ses-
sion. The exercise intervention included two weekly HIIT sessions, each with 2 to 4
intervals of 2 to 4 minutes at 85% to 95% of peak heart rate. The study was
Abbreviations: AEs, adverse events; (B)EP, (bleomycin) etoposide and cisplatin; CBCT, cisplatin-based chemotherapy; CPET, cardiopulmonary exercise test; CRF, cardiorespiratory fitness; CT,
computed tomography; dRVVT, diluted Russell's viper venom test; DXA, dual-energy X-ray absorptiometry; HI(I)T, high-intensity (interval) training; HR, heart rate; RCT, randomized controlled
trial; TAST, testicular cancer and aerobic- and strength training; TC, testicular cancer; TE, thromboembolic events.
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prematurely discontinued after inclusion of 19 of the planned 94 patients, with nine
patients randomized to the intervention arm and 10 to the control arm. Three
patients in the intervention arm developed TE complications; two with pulmonary
embolism and one with myocardial infarction. All three patients had clinical stage IIA
TC. No TE complications were observed among patients in the control arm. Our
observations indicate that high-intensity aerobic training during CBCT might increase
the risk of TE events in TC patients, leading to premature closure of the TAST-trial.
K E YWORD S
cisplatin-based chemotherapy, high-intensity training, testicular cancer, thromboembolic events
1 | INTRODUCTION
The potential benefits of exercise training during and after cancer treat-
ment have increasingly gained interest. Current evidence suggests that
exercise is safe and effective to maintain or improve physical fitness and
patient-reported outcomes both during and after treatment.1-3 Cancer
patients and survivors are therefore generally recommended to avoid
inactivity and follow the public guidelines for physical activity if feasi-
ble.4-6 However, the optimal intensity of exercise during cancer treat-
ment remains unclear; particularly, the efficacy, feasibility and safety of
high-intensity training (HIT) across subgroups of cancer patients.7
Previous randomized controlled trials (RCTs) examining effects
and safety of HIT during chemotherapy have demonstrated beneficial
effects and few adverse events (AEs).8-12 Notably, only a small minor-
ity of patients in these studies were treated with cisplatin.
Cisplatin-based chemotherapy (CBCT) is standard treatment for
metastatic germ cell testicular cancer (TC).13 During CBCT, TC
patients frequently experience reduced cardiorespiratory fitness (CRF)
and muscle strength. Furthermore, TC survivors who have received
CBCT are at risk of chronic fatigue and development of metabolic syn-
drome.14,15 Given the risk of acute and long-term AEs after treatment
of metastatic TC, identification of risk-reducing interventions is of
high relevance. To the best of our knowledge, only one study has
examined the effects of exercise during chemotherapy for TC,
suggesting that high-intensity strength training was safe.16
In the “Testicular cancer and Aerobic and Strength Training trial”
(TAST-trial), we aimed to evaluate the effects of high-intensity interval
training (HIIT) on CRF in TC patients during CBCT. Here, we report on
the unexpected high number of thromboembolic (TE) events among
the patients randomized to the intervention.
2 | METHODS
2.1 | Study design and patients
The TAST-trial was a two-arm (1:1 ratio) national multicenter RCT,
comparing change in CRF measured by peak oxygen uptake (VO2peak)
in TC patients who during CBCT underwent a training program
including HIIT, to controls who received a single lifestyle counseling
session. The randomization was computerized in an equal allocation
and the patients were stratified by study center.
Patients were recruited at four university hospitals in Norway:
Oslo University Hospital, University Hospital of North of Norway,
Haukeland University Hospital and St. Olavs University Hospital, from
November 2015 to November 2016. Inclusion criteria were men aged
18 to 60 years with metastatic germ cell TC and with a treatment plan
of 3 or 4 cycles of cisplatin combined with etoposide (EP) or with
etoposide plus bleomycin (BEP). The BEP/EP regimens were given in
3-week cycles and consisted of cisplatin 20 mg/m2 Day 1 to 5,
etoposide 100 mg/m2 Day 1 to 5, and for BEP, bleomycin 30 mg Day
1, 5 and 15. Exclusion criteria were major physical or mental comor-
bidity, or not able to perform a maximal cardiopulmonary exercise test
(CPET); that is, unable to cope with the equipment, or developing
arrhythmias, cardiac ischemia or infarction, severe exercise-induced
hypoxemia, or systolic blood pressure above 250 mmHg.
2.2 | Study assessments
All participants underwent the same assessments before and after the
intervention period. The primary outcome was VO2peak measured
What's new?
Exercise is widely acknowledged to be beneficial for cancer
patients, but certain subgroups may experience adverse
effects. Patients with testicular cancer who take cisplatin-
based chemotherapy often experience reduced cardiovascular
function. In this study, the authors observed an increase in
thromboembolic events among testicular cancer patients tak-
ing cisplatin who engaged in HIIT twice a week. In a random-
ized trial, 3 out of 9 patients in the exercise arm experienced
TE events, including myocardial infarction and pulmonary
embolism, compared with 0 of 10 patients in the control arm.
The study was cut short due to the increased risk.
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during a CPET using a continuous graded exercise protocol on a tread-
mill until exhaustion. Peak heart rate (HRpeak) assessed by 12-leads
electrocardiography (ECG) was also measured during the CPET. If the
rest and exercise-ECGs were normal and no cardiac symptoms
occurred, no further cardiac examinations were performed. For safety
reasons, pulmonary function, blood pressure and saturation were also
measured before, during and after CPET, all under supervision of an
exercise physiologist and a physician. Other assessments included,
muscle strength tests, dual-energy X-ray absorptiometry (DXA) scan,
routine blood tests and questionnaires.
After the discontinuation of the TAST-trial, the cases were
assessed with regard to individual susceptibility for TE complications.
Laboratory investigations were performed 3 to 10 months after the
TE events for deficiencies of the natural anticoagulants (protein S,
protein C and antithrombin), presence of lupus anticoagulant (subtest
diluted Russell's viper venom test (dRVVT) and silica clotting time,
anti-cardiolipin antibodies and anti-beta2 glycoprotein I abs) and the
presence of point mutations in the coagulation factor (F)V gene
(c.1601G>A; FV Leiden) and in the prothrombin gene (c.*97G>A). The
prechemotherapy computed tomography (CT) scans were re-evalu-
ated for signs of thrombosis in large vessels or pulmonary embolism.
2.3 | Intervention arm
Because CRF was the primary outcome of the trial, we composed an
intervention that emphasized high-intensity aerobic exercise. The
intervention included two one-to-one supervised sessions per week
for 9 or 12 weeks depending on the number of chemotherapy cycles.
Walking uphill on a treadmill was the primary choice of exercise, but
ergometer-cycling, rowing and out-door walking were possible alter-
natives. Each session consisted of 10 minutes warm-up at 60% to
70% of HRpeak, followed by HIIT; that is, 2 to 4 intervals of 2 to
4 minutes at 85% to 95% of HRpeak, (high-intensity zone); separated
by 2 minutes’ active recovery, and followed by 10 minutes’ cool-down
(Figure 1). Thereafter, an optional 15 minutes strength training was
performed, depending on the patient's energy level. HRpeak obtained
during the pre-intervention CPET was used to calculate the training
zones. The HR and the Borg Rating of Perceived Exertion Scale17
were registered each minute during the HIIT. If the patients felt
unwell before or during a session, the physiotherapists/personal
trainers were instructed to make individual adaptations regarding the
intensity, duration and/or number of intervals. If the patient's condi-
tion was not compatible with HIIT, the planned session was post-
poned or canceled.
2.4 | Control arm
During the first chemotherapy cycle, patients in the control arm
received a 30-minute counseling session on general lifestyle
recommendations.
2.5 | Sample size calculation
Based on our experience from a pilot study,18 we expected reductions
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Minutes
F IGURE 1 Typical session including 10 minutes warm-up, four intervals of high-intensity (85%-95% of HRpeak) physical exercise separated by
active recovery, and 10 minutes cool-down. HR, heart rate; HRpeak, peak heart rate (beatmin−1) [Color figure can be viewed at
wileyonlinelibrary.com]
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group and 9 mL/kg/min in the exercise group, with a SD of 5 mL/kg/
min for both groups. Upfront sample size calculations showed that we
needed 47 patients in each group to detect a mean group difference
in change of VO2 peak during chemotherapy of 5 mL/kg/min with a
SD of 7 mL/kg/min (two-sided significance level of 5%, power of 90%
and 10% dropout).
TABLE 1 Baseline characteristics of the patients in the intervention- and control arm, and of each case who developed a thromboembolic
event
Intervention arm (n = 9) Control arm (n = 8) Case 1 Case 2 Case 3
Age, year (median [range]) 31 (21-50) 31 (25-56) 21 43 30
Cancer characteristics (n or median [range])
Histology
Seminoma 2 4
Nonseminoma 7 4 1 1 1
Stagea




hCG (IU/L) 3.2 (0.1-7.6) 4.1 (0.1-31.1) 3.4 6.3 3.5
AFP (kU/L) 3 (1-117) 6 (2-1294) 3 5 117
LDH (U/L) 172 (137-348) 183 (161-329) 196 148 140
Prognosis group




BEP × 3 8 5 1 1 1
EP × 4 1 3
Khorana scoreb (n)
0-2 9 8 1 1 1
≥3 0 0
Lipids and glucose (median [range])
Cholesterol (mmol/L) 4.7 (3.3-6.3) 5.0 (3.6-6.2)c 4.7 5.0 6.3
HDL-cholesterol (mmol/L) 1.6 (0.8-1.8) 1.1 (0.8-1.7)c 1.6 1.7 1.0
LDL-cholesterol (mmol/L) 2.9 (2-4.7) 3.5 (2.3-4.9)c 2.8 3.0 4.7
Triglycerides (mmol/L) 1.4 (0.6-1.7) 0.9 (0.8-1.9)c 1.6 1.4 1.6
Glucose (mmol/L) 5.5 (4.6-6.2) 5.4 (4.9-6.9)c 5.1 5.1 5.9
HbA1c (%) 5.0 (4.8-5.2)d 5.3 (5.0-5.6)e 4.9 5.0 5.1
Other variables relevant to thrombosis (median [range] or n)
VO2peak (mL/kg/min) 43.0 (33-56)
f 41.6 (30-51)g 35.0 46.3 32.8
% of expected (%) 102 (67-120)f 91 (76-104)g 67 109 68
BMI (kg) 24.9 (21.6-31.7) 28.9 (21.4-32.5) 29.9 24.8 31.7
Smoking
No (never/stopped) 7 7 1 1
Yes, occasionally 2 1 1
Meeting PA guidelines precancerh
Yes 8 6 1 1
No 1 2 1
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3 | RESULTS
The TAST-trial was prematurely discontinued after inclusion of 19 of
the planned 94 patients, due to an unexpected high number of TE
events among the patients in the intervention arm. This decision was
made by the principal investigator in accordance with recommenda-
tions from the safety evaluation committee.
During the 12 months inclusion period, nine patients were ran-
domized to the intervention arm and 10 to the control arm. After ran-
domization, one patient withdrew and another was excluded due to
change in planned chemotherapy, leaving eight patients in the control
arm. Three of nine patients (33%, 95% confidence interval [CI] 7%-
70%) in the intervention arm developed TE complications, as com-
pared to none in the control arm. Two of the patients developed pul-
monary embolism and one patient myocardial infarction. All three
patients had nonseminoma TC, Royal Marsden Hospital clinical Stage
IIA, and were classified as International Germ Cell Cancer Collabora-
tive Group good prognosis group.19
Two patients, both in the control arm, received anticoagulants
at study entry: One patient as treatment for renal vein thrombosis,
the other as thromboprophylaxis due to inferior caval vein com-
pression. Baseline characteristics of the patients are presented in
Table 1.
3.1 | Case reports
3.1.1 | Case 1
A 21-year-old man completed four of seven planned supervised exer-
cise sessions before being diagnosed with pulmonary embolism. He
preferred to switch between ergometer cycle, treadmill and rowing
machine. In the four completed sessions, 9 of the 16 planned intervals
were in the HIIT zone (Table 2 and Figure S1A).
On Day 10 of the second BEP cycle (7 days since last exercise
session), he experienced cough and thoracic pain. The CT scan at the
local emergency department revealed cryptogenic organizing pneu-
monia, and treatment with prednisolone and azithromycin was initi-
ated. On Day 15 of the second BEP cycle, repeat CT scan showed
thrombosis of the left internal and common iliac veins, and a large
embolism in the right pulmonary artery. He received dalteparin subcu-
taneously for 6 months.
Potential risk factors for venous TE
Re-evaluation of the prechemotherapy CT scan did not reveal venous
thrombosis or pulmonary embolism. The patient's grandfather had a pro-
voked deep vein thrombosis after orthopedic surgery. The patient was
heterozygous for the FV Leiden mutation, increasing his risk of venous
TE twofold to sixfold. Lupus anticoagulant was weakly positive in one
subtest (dRVVT), and still weakly positive after 13 and 30 weeks. Taken
together, this patient had a modestly increased risk of venous TE. All
other coagulation analyses were within reference ranges.
3.1.2 | Case 2
A 43-year-old man completed nine of 10 planned supervised exercise
sessions before diagnosed with pulmonary embolism. He preferred to
walk uphill on the treadmill. In the nine completed sessions, 13 of 40
planned intervals were in the HIIT zone (Table 2 and Figure S1b).
On Day 15 of the second BEP cycle (3 days since last exercise
session), a preplanned evaluation CT scan detected large thrombotic
masses in the inferior caval vein and bilateral pulmonary embolism. In
retrospect, the patient had experienced increasing inspiratory thoracic
TABLE 1 (Continued)
Intervention arm (n = 9) Control arm (n = 8) Case 1 Case 2 Case 3
Comorbidity (self-reported)
Yes 5i 3j 1k 1l
No 4 5 1
Abbreviations: AFP, alpha-fetoprotein; BEP, bleomycin, etoposide and cisplatin; BMI, body mass index; EP, etoposide and cisplatin; HbA1c, glycated hemo-
globin; hCG, human chorionic gonadotropin; HDL, high-density lipoprotein; IU/L, international units per liter; kU/L, kilounits per liter; LDH, lactate dehy-
drogenase; LDL, low-density lipoprotein; mmol/L, millimole per liter; PA, physical activity; RPLN, retroperitoneal lymph node; U/L, units per liter.
aStage according to Royal Marsden Hospital Stadium.
bCancer site (testicular cancer = 1), prechemotherapy platelet count ≥350 × 109/L, hemoglobin <100 g/L, prechemotherapy leukocyte count >11 × 109/L,






hMinimum 150 minutes of moderate intensity PA or 75 minutes of high-intensity PA per week.
iPsychological distress (n = 2), muscle and skeletal disease (n = 2) and chronic lung disease (n = 1).
jHypertension (n = 1), muscle and skeletal pain/disorder (n = 2), mild/moderate asthma (n = 1) and epilepsy (n = 1).
kPsychological distress.
lMuscle and skeletal pain/disorder.
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pain and dyspnea from day seven of the second BEP cycle, which he
had not reported to health professionals. He received dalteparin sub-
cutaneously for 10 months, thereafter warfarin for 4 months.
Potential risk factors for venous TE
Re-evaluation of the prechemotherapy CT scan did not reveal venous
thrombosis or pulmonary embolism. This patient had no hereditary
factors for venous TE events, and all coagulation analyses were within
reference ranges.
3.1.3 | Case 3
A 30-year-old man completed 12 of 14 planned supervised exercise
sessions prior to a myocardial infarction. He preferred to walk uphill
on the treadmill. In the 12 completed sessions, 38 of 48 planned inter-
vals were in the HIIT zone (Table 2 and Figure S1c).
He experienced chest-pain from Day 6 of the third BEP cycle
(3 days since last exercise session). After 12 hours of persistent pain,
he consulted his oncologist. He was immediately referred to the local
emergency department where he was diagnosed with ST-segment
elevation myocardial infarction. Peak troponin I was 8541 ng/L
(<35 ng/L). Angiography showed a clinically nonsignificant stenosis of
the left anterior descending artery. Coronary angiography indicative
of thromboembolic rather than atherosclerotic origin in TC patients
during CBCT has been described previously.20 He was given ticagrelor
for 3 months and long-term acetylsalicylic acid and atorvastatin.
Potential risk factors for arterial TE
He had hereditary risk factors for cardiovascular disease, as one par-
ent had angina pectoris, and several family members had hypercholes-
terolemia. All coagulation analyses were within reference ranges. His
body mass index was 32 kg/m2. He had no signs of hypertension
(blood pressure 110/75 mmHg) or hyperglycemia. He was a never-
smoker. Although within reference ranges, the lipid profile at baseline
was unfavorable (Table 1). Taken together, this patient had a modest
increased risk of arterial TE.
All three cases completed three cycles of BEP as planned, achiev-
ing durable complete remissions.
4 | DISCUSSION
Three of nine patients in the intervention arm experienced a TE event,
that is, pulmonary embolism and myocardial infarction. Since the risk
of pulmonary embolism or myocardial infarction are expected to be
low in patients with TC during or shortly after CBCT, our observations
indicated a substantially higher rate than reported in the literature
(33% vs 0-15%). Pretreatment, none of the cases had any TC-specific
risk factors for TE events, such as large abdominal lymph nodes, ele-
vated LDH or central venous access. In accordance with national
guidelines for treatment of TC in Norway, they did not receive pri-
mary thromboprophylaxis. Case 1 and 3 had predisposing factors for
venous and arterial TE events, respectively.20 Although we are fully
aware that the TE events in the intervention arm might have been a
play of chance, we find it hard to ignore that the HIIT might have con-
tributed to the unexpected high number of TE events. Proposed
mechanisms for possible interactions between CBCT and high-inten-
sity aerobic exercise that can potentiate the risk of TE events are
described after a review of the literature.
4.1 | TE events during CBCT—review of the
literature
Within the three main concepts; testicular neoplasms, cisplatin and
thromboembolism; MeSH terms with variations were searched in
titles, abstracts and author keywords in MEDLINE (Ovid) and Embase
TABLE 2 Number of intervals and minutes when the cases reached high-intensity training zone (85%-95% of peak heart rate) for each
session
First chemotherapy cycle Second chemotherapy cycle Third chemotherapy cycle
Week 1 2 3 1 2 3 1 2 3
Case 1
Day 2 4 9 11 3
Intervals (n) 2 3 2 2 0
Minutes (n) 5 8 6 7 0
Case 2
Day 3 5 10 12 15 19 1 3 12
Intervals (n) 0 1 2 1 4 1 2 1 1
Minutes (n) 0 1 5 2 6 1 4 1 1
Case 3
Day 3 5 12 17 19 1 3 10 17 19 1 3
Intervals (n) 2 4 2 4 4 4 1 3 3 3 4 4
Minutes (n) 6 12 6 11 12 10 1 8 10 8 15 12
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1980 to 2019. The Medical Library at the University of Oslo per-
formed the search in August 2019. The search was limited to English
language. Detailed search strategies are described in Supporting Infor-
mation File S1. After screening and assessing 567 unique abstracts
and full-text articles for eligibility, 15 articles with TE events as an
endpoint in TC patients during CBCT were included (Table 3). Studies
limited to venous access-associated thrombosis were excluded. The
selection process is further detailed in Figure S2.
The majority of studies were retrospective, apart from two stud-
ies with a prospective design,20,21 and one where the design was not
reported.22 The studies were heterogeneous and study populations
were often poorly described. Thus, the expected rate of TE events
among TC patients in clinical stage IIA without elevated LDH or cen-
tral venous access is not deductible. During CBCT, 14 studies
reported on incidence rates of venous TE events, ranging from 2% to
24% (Table 3).20-33 The reported rates of venous TE events presented
in Table 3 consists of deep vein thrombosis and pulmonary embolism,
except for one study26 which also includes superficial vein thrombo-
sis. The reported incidence rate of pulmonary embolism ranged from
0% to 11%.20-24,26-33 Nine studies reported on the incidence rate of
myocardial infarction ranging from 0% to 4%.20-23,27,28,32-34 Eight
studies reported on the incidence rate of both pulmonary embolism or
myocardial infarction, ranging from 0% to 15%.20-23,27,28,32,33
Among cancer patients in general, the following are identified as
TE risk factors: Platelet count >350 × 109/L, hemoglobin <10 g/dL,
leukocyte count >11 × 109/L, BMI > 35 kg/m2, CBCT and TC.35,36
These risk factors do not seem to apply for TC patients receiving
CBCT. In TC patients receiving CBCT, several studies identify retro-
peritoneal lymph nodes >5 cm, central venous access and elevated
serum LDH as risk factors for TE (Table 3).22-25,27,29,32
4.2 | TE events during CBCT—possible
mechanisms
Venous thrombi are formed when the physiologic balance between
procoagulant and anticoagulant reactions is disrupted. Blood coagulation
is initiated, followed by amplification and propagation phases involving
activated platelets.37 Platelet activation and aggregation are contributing
factors in the mechanism of arterial thrombus formation.38 Proposed
mechanisms for the increased risk of TE events during CBCT in TC
patients are that CBCT induces endothelial damage39 and upregulation of
procoagulant factors such as coagulation factor VIII.20,40 As a hypothetical
consequence, endothelial damage with subsequent exposure of the sub-
endothelium and release of collagen and fibronectin to the blood could
activate platelets. Moreover, CBCT-induced endothelial damage may lead
to exposure of tissue factor, which can initiate blood coagulation.41,42
4.3 | The association of HIT and TE risk
Blood is known to be hypercoagulable immediately after strenuous
exercise, mainly due to an increased level of coagulation factor VIII.43
Studies have shown that HIT sessions are followed by a transient
increase in platelet activation and aggregation.44-46 The increase in
factor VIII and the degree of platelet activation and aggregation after
exercise are associated with the intensity of the exercise.47-49 Fur-
thermore, the degree of platelet activation after HIT is reported to be
related to individual physical fitness, leaving untrained individuals in at
higher risk than well-trained individuals.43
4.4 | Possible increased TE risk during CBCT
combined with HIT
The limited existing data on HIT during CBCT have not included reports
on TE events. Adamsen et al examined the effects of an exercise interven-
tion including HIT during chemotherapy. Among 135 patients randomized
to the intervention, seven TC patients received CBCT.8 No patients had
TE events during the six-week intervention (L. Adamsen, personal com-
munication, July 2019). One could speculate whether high-intensity train-
ing adds to the risk of TE events of CBCT among TC patients, rendering
them more prone to TE events. It is possible that exercise programs with
lower intensity and more gradual increase in intensity might be more
favorable than the HIIT program in the TAST-trial.
4.5 | Limitations
The small number of included patients in the TAST-trial is an obvious
limitation. Possibly, this is an accidental observation unrelated to the
HIIT, reflected in the wide CI. Furthermore, our observations are after
high-intensity aerobic exercise, thus not representative for physical
activity with low- and moderate intensity or strength training. We are
unable to estimate an exact cut-off for the training intensity regarding
the risk of TE events. Our observation is also limited to HIT during
CBCT, not to training after completing CBCT. Future research on TC
and exercise training may consider exercise protocols with lower
intensity during CBCT or HIT interventions after completion of CBCT.
5 | CONCLUSION
It is well known that TC patients are at risk of TE events during CBCT.
Two of the three cases with TE events had risk factors for such
events. Our study raises the possibility that HIIT during CBCT adds to
CBCT-induced hypercoagulability.
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